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Abstract 
We present data on mitochondrial DNA deletions and mitochondrial diseases. The mechanism of their occurrence is discussed on the 
basis of deletion breakpoints and particularly with the slippage mispairing hypothesis. As the correlation between the genotypes and the 
phenotypes i not always straightforward, a classification of mitochondrial diseases is suggested according to the genotype (deletions, 
depletions and duplications, mutations affecting structural genes or tRNA genes) rather than the phenotype. The effect of mitochondrial 
DNA alterations on the expression of nuclear encoded proteins is presented, and the nucleus can be found to respond ifferently but in a 
coordinate way according to the kind of mitochondrial DNA alteration. The search for a nuclear gene affecting the expression of Leber's 
disease could not show any correlation between the alleles of TAP2 (transporter antigen peptide) and the expression of the disease. 
Finally, we present new data on another class of myopathies, namely Duchenne muscular dystrophy (DMD), where mitochondria could 
play an unexpected role in the metabolism of calcium. In some patients with DMD a mitochondrial calcium binding protein that is mainly 
located in the mitochondrial matrix and which is named 'calmitine' was found to disappear. We have thus cloned its cDNA and found 
that it was identical with to calsequestrine which is a high-capacity but low-affinity Ca 2+ binding protein from the sarcoplasmic 
reticulum. 
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1. Introduction 
The mitochondrial genome is organized as a covalent 
circular double stranded DNA molecule of 16569 base 
pairs in human (Anderson et al., 1981) [1], encoding 2 
ribosomal RNAs, 22 tRNAs and 13 proteins of the respira- 
tory chain complexes according to a specific genetic code. 
Owing to its extreme compactness it seemed quite unlikely 
that important reorganizations such as deletions would still 
be compatible with life. However, the first description of a 
profound anomaly of the mitochondrial DNA was put 
forward in t987 by Boursot et al. [2] who discovered that 
wild-type Bulgarian mice contain a large deletion in the 
coding region of the mitochondrial genome. The interest- 
ing point they observed was the DNA heteroplasmy, that 
is, the cohabitation of the wild-type DNA molecule to- 
gether with the deleted one, therefore allowing the mice to 
be perfectly alive. One year later a similar description was 
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given in human pathology by Holt et al. [3] in the general 
field of mitochondrial myopathies. However, the clinical 
features of what is called myopathy broadly vary and 
encompass many discrepancies in the clinical status of the 
patients. 
2. Role of the mitochondrial DNA in myopathies 
2.1. Description of the first case of Kearns-Sayre syn- 
drome associated with muscle mitochondrial DNA deletion 
At the same time [4] we described the archetype of 
mitochondrial myopathy namely Kearns-Sayre syndrome 
which was first reported in a journal of ophthalmoplegia 
[5]. This syndrome is characterized by a ptosis, a retinitis 
pigmentosa, progressive xternal ophthalmoplegia, cardiac 
defect, and an onset generally before 20 years old. Enzy- 
matic defects of complex I (NADH dehydrogenase), com- 
plex III (ubiquinone cytochrome-c reductase), and com- 
plex IV (cytochrome-c oxidase) as well as an increased 
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level of proteins in the cerebro spinal fluid are character- 
istic of that disease. The histological examination also 
showed ragged red fibers upon Trichrome gomori staining, 
cytochrome-c oxidase negative fibers as well as abnormal 
mitochondria. Southern blot analysis upon linearization of 
the mt DNA with BamHI revealed one normal sized 
populations of mt DNA in the lymphocytes while the 
muscle contained an additional one of 12 kb. By using a 
battery of restriction enzymes and mitochondrial DNA 
probes prepared before hand, we could show that the 
shorter mt DNA was indeed deleted in the coding region 
from its approximative position of 7850 ( + 400 base pairs) 
to 13000, removing structural genes as well as tRNA 
genes. The cohabitation of these two genomes within the 
same individual, called heteroplasmy, is probably the 
unique way to maintain living activities for the patient. 
This finding, could therefore explain the mitochondrial 
dysfunctions described above. Our findings were then 
confirmed by DiMauro's group [6]. 
2.2. Mapping the deletion at the nucleotidic level 
Within a year later, with the fortunate advent of the 
polymerase chain reaction, we were able to more precisely 
locate the deletion from position 8571 to 13237 [7]. The 
reorganized genome could encode for a potential fusion 
polypeptide of 35 000 Da molecular mass between the 15 
N-terminal amino acid residues of ATP synthetase subunit 
6, and the 303 C-terminal amino acids of NADH dehydro- 
genase subunits. In this case no peculiar feature could be 
evidenced from the DNA sequence except for a short 
inverted sequence ATCXTA at the breakpoint, suggesting 
a simple double strand break. In mice with heteroplasmic 
deletion in the coding region, no peculiarity in the DNA 
sequence could be evidenced [8]. In the meantime other 
deletions were mapped. 
2.3. Generalization of  our first observation 
Samples from different parts of Europe were studied by 
Southern blot and mapped as previously described. Most 
of them, with a few exceptions, lay in the large part of the 
mt DNA between OH and OL [9]. That region is single- 
stranded during the first part of the replication cycle of 
mammalian mt DNA suggesting thus that the deletions 
occur during the first part of the asymmetrical replication 
cycle of mt DNA [10]. 
2.4. A kinetic model 
A kinetic model was suggested which would account 
for the persistence of heteroplasmy. The main idea is that 
the circularization of the displaced heavy strand occurs due 
to the lag in priming and replication of the light strand [7]. 
Following the circularization a DNase and a ligase would 
release the single circular-stranded heavy q molecule. At- 
tempts to trap this transient intermediate molecule by PCR 
were, however, unsuccessful (unpublished ata). 
2.5. Mapping the deletions at the nucIeotidic level reveals 
that different mechanisms may account for the deletions 
The precise mapping at the nucleotidic level of the 
deletions from 24 patients with Kearns-Sayre syndrome 
associated with progressive xternal ophthalmoplegia p - 
tients revealed that the breakpoints of the deletions oc- 
curred at the level of direct repeats, partial direct repeats or 
no repeat sequences suggesting that different mechanisms 
were responsible for these deletions [11,12]. The length of 
the deletions varies between 2310 bp and 8476 bp and 
spans from positions 5586 to 15 925, preserving the origins 
of replication. Twelve cases are common deletions [13] of 
almost identical size of 4977 bp spanning from 8482 to 
13 459 but in one case there is a retention of one adenosine 
[11-14] residue at position 13446 of the direct repeat 
located near the heavy-strand origin of replication. 
2.6. Slippage mispairing as a possible deletion mechanism 
Slippage mispairing of the first direct repeat of the 
displaced heavy strand to the second direct repeat of the 
light strand located downstream, which serves as a matrix 
for the heavy-strand DNA replication, may occur [14]. One 
example is provided in reference [l l] showing a 4-nucleo- 
tide difference in cloned mt DNAs from one patient sug- 
gesting once again a slippage mispairing and previous or 
current dynamic processes in the deletion formation. Re- 
cent in vitro and in vivo experiments on mammalian 
mitochondrial DNAs suggest that slipped mispairing is 
indeed responsible for the main class of mammalian muta- 
tions [15]. Hence, these data suggest hat there may be 
three classes of deletions with at least two different mecha- 
nisms: the first one would be a perfect or imperfect 
slippage mispairing during the asymmetrical replication 
cycle of the mt DNA by DNA polymerase gamma [16], the 
second one would be a strand break, by a DNA topoiso- 
merase or DNA recombinase for example, followed by 
ligation by a DNA ligase. 
In these two main classes of deletions, enzymes and 
factors involved in mt DNA repairing and replication 
would be come into play during the early stages of ovoge- 
nesis, allowing the clonal amplification of one deleted mt 
DNA species. The theoretical twofold replicative advan- 
tage of the deleted molecule by a factor of about two, due 
to a twofold faster rate, would account for the same 
number of deleted molecules as compared with the wild 
type during the 9 or 10 replication cycles of ovogenesis. 
Then random distribution of the two genomes in the 
different organs would provide the different phenotypes 
we observe in this kind of disease. Maternal transmission 
was reported in one family [17] but was not confirmed in 
any other one [18]. Hypoxemia was associated with a 
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higher mitochondrial DNA damage rate [19]. Moreover, 
Doxorubicin-induced cardiotoxicity was also associated 
with a 4 kb deletion of the mt DNA in mice. Coenzyme Q 
10 administration prevents the mt DNA deletion, suggest- 
ing the involvement of some free radicals in the genesis of 
mt DNA deletion [20]. 
2.7. Genotype versus pheno~pe 
Even if Kearns-Sayre syndrome appears to be well 
defined from the clinical point of view, our data show that 
the size and position of deletions differ among individuals. 
Also the various repartition of both genomes in the differ- 
ent tissues shows that the percentage of heteroplasmy may 
vary in the muscles of these patients from 34 to 68%, 
though the enzymatic activities are affected to the same 
extent [21]. However, a patient displaying 30% of deleted 
molecules has no detectable nzymatic defect, although e 
is ill. The length of the deletion may be an important factor 
contributing to the disease, since one patient contained 
25% of a large deletion of 8136 bp but presented only a 
complex I defect, though part of complex IV was deleted. 
Hence the threshold effect of the deletion is far from being 
understood at the enzymatic level as well as at the body 
level. Worthwhile to note, a patient initially misdiagnosed 
as presenting psychosomatic disorders, was actually a 
Kearns-Sayre patient with deletion of the mt DNA [22]. 
The culture of heteroplasmic myoblasts or fibroblasts 
revealed uneven distribution of normal and deleted mt 
DNAs. Some cells had various proportions of both genomes 
whereas others contained only the normal ones. Cells 
containing dmt DNA grew more slowly, but apparently the 
replication was effective. It is worth mentioning that fi- 
broblasts need uridine supplement to maintain the deletion, 
while lymphocytes do not, which demonstrates once more 
the importance of tissue specificity when studying these 
diseases [23]. 
Other factors may influence the expression of the patho- 
logical phenotype. For example, in case of intramitochon- 
drial complementation it is possible that the fusion 
polypeptide possibly can play a role in the pathogenesis by 
destabilizing the membrane complexes. To check this hy- 
pothesis we have in a first step searched for the presence 
of the fusion transcript in the lymphocytes of a patient 
presenting with Kearns-Sayre syndrome. The transcript 
was revealed by Northern blot [24]. In vitro protein synthe- 
sis was performed in the presence of emetine, which 
inhibits cytoplasmic protein synthesis, and L- 
[35S]methionine. No fusion polypeptide could be detected 
though the percentage of heteroplasmy was of 25%. We 
concluded that in these lymphocytes, beyond the fact that 
the fusion protein could be rapidly degraded, no comple- 
mentation by the tRNA originating from the wild-type 
genome occurs. Therefore both genomes hould be sepa- 
rate entities in different mitochondria. However, such a 
possibility should not be a general rule in other tissues 
where the percentage of deleted molecule is higher, or for 
other kinds of deletions. For example complementation for
translation seems to occur along the muscle fibers [25]. 
Also, experiments on HeLa cells that were repopulated 
with various amounts of dmt DNAs revealed that, below a 
threshold of 60%, translational complementation could 
occur, since the reorganized genome can be translated. On 
the other hand, above this value, translation and the activ- 
ity of cytochrome-c oxidase are impaired [26]. 
2.8. Mitochondrial DNA mutations and diseases 
We would like to suggest a possible classification of 
mitochondrial diseases according to the mutation that could 
be put forward [27]: 
Class I represents structural gene mutations uch as in 
LHON (Leber's hereditary optic neuropathy) and NARP 
(neurogenic muscle weakness, ataxia and retinitis pigmen- 
tosa), as well as some cases of Leigh's syndrome. 
Class II comprises transfer and ribosomal RNA gene 
mutations as in MELAS (mitochondrial encephalomyopa- 
thy, lactic acidosis and stroke-like episodes), MERRF 
(myoclonic epilepsy with ragged red fibers), or deafness 
with aminoglycosides. 
Class III involves the mt DNA deletions, depletions and 
duplications. 
2.9. Mitochondrial DNA L'ersus nuclear DNA 
The results provided here designate the mitochondrial 
DNA as a primary cause of myopathy. However, mito- 
chondrial DNA alterations may induce a feedback effect 
on nuclear gene expression. This hypothesis turned out to 
be correct in three types of myopathy, namely Kearns- 
Sayre syndrome, MERRF and MELAS. We have studied 
the steady state level of messenger RNA encoding the 
nuclear ATP translocase (ANTI) and ATP synthetase /3 
subunit. There was a coordinate induction of these genes in 
point mutated tRNA in MERRF and in MELAS, while 
there was a coordinate repression of these two genes in 
Kearns-Sayre syndrome [28]. This feedback effect may be 
due to the coordinate xpression of oxphos genes. The 
nucleus might attempt to compensate he lower ATP level 
due to tRNA mutations and dysfunction. On the other 
hand, segmental complementation in muscle fibers as ob- 
served in KSS may prevent his overall gene induction. 
2.10. Nuclear DNA and Leber's disease 
Leber's disease is characterized by a sudden bilateral 
optic atrophy due to optic nerve degeneration at about 20 
years old with a prevalence for young men (70%). The A 
to G mutation at position 11 778 [29] may be detected by 
allele specific amplification [30] and G to C mutation at 
position 3460 [30,31] is present in affected or non affected 
members of the same family with a maternal transmission. 
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Thus genetic or environmental factors may contribute to 
the pathological phenotype. Since there is optic nerve 
inflammation, and as there is a maternal antigen encoded 
by the mitochondrial DNA in mice [32], it seems plausible 
that Leber's disease is an autoimmune disease due to the 
association of an abnormal mitochondrial encoded 
polypeptide with a cytoplasmic antigen peptide transporter. 
In order to evaluate that possibility we have searched for 
the allele frequency of the intracellular peptide/antigen 
transporter TAP2 together with the Leber's phenotype. 
There is no special association between these three alleles 
and the expression of the phenotype [33]. Therefore it is 
still unknown why a patient develops LHON while his 
relatives do not. 
3. Role of the mitochondrial calcium binding protein, 
calmitine, in myopathies 
Other kinds of myopathies are caused by known nuclear 
gene defects as in Duchenne and Duchenne and Beker 
dystrophies. Their usual cause is due to the abnormal 
structure of the giant (2.5 million base pairs) gene located 
on chromosome X. However, the exact etiology of that 
disease is far from being understood at the molecular level 
since muscle fiber degeneration appears to be specific to 
humans and dogs, whereas no clinical sign affects the mdX 
mice having a point mutation in the DMD gene which 
prematurely stops the translation of the whole mRNA. 
From different data it seems that the dystrophin protein 
plays a key role in fiber architecture since it is a membrane 
cytoskeletal protein. Head-to-tail dimers of dystrophin 
would bind F-actin by the N-terminal part while the C- 
terminal domain would be associated with DAG (dys- 
trophin associated glycoproteins). The lack of dystrophin 
could destabilize the DAG, which form a complex on the 
sarcolemnal membrane [34]. In addition dystrophic cells 
have been shown to contain specifically higher Ca 2+ 
amount which could lead to a fiber necrosis by the activa- 
tion of Ca 2+ proteinases and nucleases. 
3.1. Relationship between calmitine and DMD 
In this connection it is interesting to note that patients 
with DMD lack a mitochondrial Ca 2÷ binding protein, 
namely the calmitine [35]. This protein is, however, pre- 
sent in mdX mice but is lacking in dystrophic C57 bl C6 
dy /dy  mice [36]. For all these reasons we thought it 
interesting to clone and sequence the cDNA of human 
calmitine, a glycoprotein with an apparent molecular weight 
of 60 000. 
3.2. Cloning calmitine reveals its being identical calse- 
questrine 
The determination of the N-terminal peptide sequence 
of the 13 amino acid residues of gel purified calmitine 
allowed for the synthesis of a combination of 1024 oligo- 
nucleotides of 29-mer that were used to screen 10000 
clones of a cDNA library from human skeletal muscles. 
Two positive clones were sequenced and compared with a 
data bank. After analysis we found that one clone was 
identical to the low affinity (K D 1 mM) but high capacity 
(30-40 Ca 2+ per molecule) calcium-binding protein of the 
sarcoplasmic reticulum calsequestrine [37]. This protein is 
a high buffering molecule which plays an important role in 
the Ca 2÷ release from the terminal cisternae of the sarco- 
plasmic reticulum during muscle contraction. We found 
that it was mainly located within the mitochondrial matrix, 
was highly rich in acid amino acid residues, and contained 
many phosphorylation sites, one N-glycosylation site, and 
a leader sequence of 28 amino acids residues [38]. This 
protein is also homologous to aspartactin, a putative 
laminin-binding protein of the extracellular matrix [39]. 
3.3. Possible role of  calmitine 
Calmitine may play a physiological role by sequestering 
intramitochondrial Ca 2+ and adjusting its free concentra- 
tion for optimal activities of the Ca 2+ activated mitochon- 
drial dehydrogenases, Such a mechanism could allow a 
better fiber homeostasis and permit the muscle of mdX to 
be functional. The calsequestrine gene is located on chro- 
mosome 1 [40]. Further studies are required to precise the 
exact role of calmitine in dystrophic fibers to foresee a 
new potential therapeutic agent to prevent muscle necrosis 
in DMD patients, a frequent disease which spontaneously 
affects one male for 8000 births. 
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